ESMO 2021: 5-Year Outcomes With Nivolumab Plus Ipilimumab in Kidney Cancer
Posted: Wednesday, September 22, 2021
Long-term follow-up from the CheckMate 214 trial presented virtually during the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract 661P) demonstrates first-line nivolumab plus ipilimumab therapy resulted in “durable efficacy benefits” compared with first-line sunitinib treatment alone in advanced renal cell carcinoma. Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues compared the conditional response and survival outcomes at 5-year versus previously recorded 3-year landmarks.
The study randomly assigned patients to receive either 3 mg/kg of nivolumab plus 1 mg/kg of ipilimumab every 3 weeks for 4 cycles followed by 3 mg/kg of nivolumab every 2 weeks or 50 mg of daily sunitinib for 4 weeks on followed by 2 weeks off. Overall, patients receiving nivolumab plus ipilimumab who were alive, progression-free, and in response at the 3-year landmark were likely to remain alive, progression-free, and in response at the 5-year landmark. The probability of a patient remaining alive, progression-free, or in response at the 5-year landmark was considered conditional survival.
Patients were divided into three groups: intermediate/poor risk, intent-to-treat, and favorable risk. In the nivolumab-plus-ipilimumab group, patients in the intermediate/poor-risk cohort had a probability of reaching both the 3-year and 5-year landmarks alive, progression-free, and/or in response of 79%, 90%, and 90%, respectively. Patients in the intent-to-treat cohort receiving the same treatment had respective probabilities of 81%, 89%, and 89%, and those in the favorable-risk cohort had respective probabilities of 85% for all categories.
Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.